BACKGROUND AIMS: Anti-thymocyte globulin (ATG) is being used increasingly to prevent graft-versus-host disease (GvHD); however, its impact on immune reconstitution is relatively unknown. We (i) studied immune reconstitution after ATG-conditioned hematopoietic cell transplantation (HCT), (ii) determined the factors influencing the reconstitution, and (iii) compared it with non-ATG-conditioned HCT. METHODS: Immune cell subset counts were determined at 1-24 months post-transplant in 125 HCT recipients who received ATG during conditioning. Subset counts were also determined in 46 non-ATG-conditioned patients (similarly treated). RESULTS: (i) Reconstitution after ATG-conditioned HCT was fast for innate immune cells, intermediate for B cells and CD8 T cells, and very slow for CD4 T cells and invariant natural killer T (iNKT) (iNKT) cells. (ii) Faster reconstitution after ATG-conditioned HCT was associated with a higher number of cells of the same subset transferred with the graft in the case of memory B cells, naive CD4 T cells, naive CD8 T cells, iNKT cells and myeloid dendritic cells; lower recipient age in the case of naive CD4 T cells and naive CD8 T cells; cytomegalovirus recipient seropositivity in the case of memory/effector T cells; an absence of GvHD in the case of naive B cells; lower ATG serum levels in the case of most T-cell subsets, including iNKT cells; and higher ATG levels in the case of NK cells and B cells. (iii) Compared with non-ATG-conditioned HCT, reconstitution after ATG-conditioned HCT was slower for CD4 T cells, and faster for NK cells and B cells. CONCLUSIONS: ATG worsens the reconstitution of CD4 T cells but improves the reconstitution of NK and B cells.
BACKGROUND AIMS: Anti-thymocyte globulin (ATG) is being used increasingly to prevent graft-versus-host disease (GvHD); however, its impact on immune reconstitution is relatively unknown. We (i) studied immune reconstitution after ATG-conditioned hematopoietic cell transplantation (HCT), (ii) determined the factors influencing the reconstitution, and (iii) compared it with non-ATG-conditioned HCT. METHODS: Immune cell subset counts were determined at 1-24 months post-transplant in 125 HCT recipients who received ATG during conditioning. Subset counts were also determined in 46 non-ATG-conditioned patients (similarly treated). RESULTS: (i) Reconstitution after ATG-conditioned HCT was fast for innate immune cells, intermediate for B cells and CD8 T cells, and very slow for CD4 T cells and invariant natural killer T (iNKT) (iNKT) cells. (ii) Faster reconstitution after ATG-conditioned HCT was associated with a higher number of cells of the same subset transferred with the graft in the case of memory B cells, naive CD4 T cells, naive CD8 T cells, iNKT cells and myeloid dendritic cells; lower recipient age in the case of naive CD4 T cells and naive CD8 T cells; cytomegalovirus recipient seropositivity in the case of memory/effector T cells; an absence of GvHD in the case of naive B cells; lower ATG serum levels in the case of most T-cell subsets, including iNKT cells; and higher ATG levels in the case of NK cells and B cells. (iii) Compared with non-ATG-conditioned HCT, reconstitution after ATG-conditioned HCT was slower for CD4 T cells, and faster for NK cells and B cells. CONCLUSIONS: ATG worsens the reconstitution of CD4 T cells but improves the reconstitution of NK and B cells.
Authors: M Hoegh-Petersen; S Sy; A Ugarte-Torres; T S Williamson; M Eliasziw; A Mansoor; Y Liu; S Liu; P Podgorny; F Khan; P R Duggan; D A Stewart; J A Russell; J Storek Journal: Leukemia Date: 2011-07-29 Impact factor: 11.528
Authors: Mark A Exley; Lydia Lynch; Bindu Varghese; Michael Nowak; Nadia Alatrakchi; Steven P Balk Journal: Clin Immunol Date: 2011-05-13 Impact factor: 3.969
Authors: B Federmann; M Hägele; M Pfeiffer; S Wirths; M Schumm; C Faul; W Vogel; R Handgretinger; L Kanz; W A Bethge Journal: Leukemia Date: 2010-10-14 Impact factor: 11.528
Authors: A Bacigalupo; T Lamparelli; G Milone; M P Sormani; F Ciceri; J Peccatori; A Locasciulli; I Majolino; P Di Bartolomeo; F Mazza; N Sacchi; S Pollicheni; V Pinto; M T Van Lint Journal: Bone Marrow Transplant Date: 2009-07-06 Impact factor: 5.483
Authors: Lisa V E Oostenbrink; Emma S Pool; Cornelia M Jol-van der Zijde; Anja M Jansen-Hoogendijk; Carly Vervat; Astrid G S van Halteren; Robbert G M Bredius; Frans J W Smiers; Maarten J D van Tol; Marco W Schilham; Arjan C Lankester; Alexander B Mohseny Journal: Bone Marrow Transplant Date: 2021-05-03 Impact factor: 5.483
Authors: Kareem Jamani; Judy MacDonald; Martin Lavoie; Tyler S Williamson; Christopher B Brown; Ahsan Chaudhry; Victor H Jimenez-Zepeda; Peter Duggan; Jason Tay; Douglas Stewart; Andrew Daly; Jan Storek Journal: Blood Adv Date: 2016-11-30
Authors: Z Al-Kadhimi; Z Gul; M Abidi; L G Lum; A Deol; W Chen; H Jang; C Ozust; A Langston; E Waller; J Uberti Journal: Bone Marrow Transplant Date: 2017-06-05 Impact factor: 5.483